{"id":"https://openalex.org/W110348379","doi":"https://doi.org/10.15272/ajbps.v2i11.55","title":"Study of Imatinib Mesylate Treated Patients sufferening from Chronic Myeloid Leukemia","display_name":"Study of Imatinib Mesylate Treated Patients sufferening from Chronic Myeloid Leukemia","alternate_titles":[],"publication_year":2012,"publication_date":"2012-09-09","ids":{"openalex":"https://openalex.org/W110348379","doi":"https://doi.org/10.15272/ajbps.v2i11.55","mag":"110348379"},"language":"en","primary_location":{"id":"mag:110348379","doi":"https://doi.org/10.15272/ajbps.v2i11.55","is_oa":false,"landing_page_url":"https://www.abacademies.org/articles/study-of-imatinib-mesylate-treated-patients-sufferening-from-chronic-myeloid-leukemia.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764445909","display_name":"Asian journal of biomedical and pharmaceutical sciences","issn_l":"2249-622X","issn":["2249-622X","6299-722X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Asian journal of biomedical and pharmaceutical sciences","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W110348379"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Amit Kumar Dutta","orcid":"https://orcid.org/0000-0002-5111-7861","observed_orcids":["https://orcid.org/0000-0002-5111-7861"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Amit Kumar Dutta","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5111-7861","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"N. Ganesh","orcid":"https://orcid.org/0009-0006-9652-9022","observed_orcids":["https://orcid.org/0009-0006-9652-9022"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Ganesh","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-9652-9022","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055117737","display_name":"Nand Kishore Sah","orcid":"https://orcid.org/0000-0002-8083-523X","observed_orcids":["https://orcid.org/0000-0002-8083-523X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nand K. Sah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5065601795","display_name":"A. Vani","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Vani","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"11","first_page":"24","last_page":"27"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9430000185966492},{"id":"https://openalex.org/keywords/imatinib-mesylate","display_name":"imatinib mesylate","score":1.0},{"id":"https://openalex.org/keywords/interferon-alpha","display_name":"interferon-alpha","score":0.9390000104904175},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.5590000152587891},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.8809999823570251},{"id":"https://openalex.org/keywords/accelerated-phase","display_name":"accelerated phase","score":0.5379999876022339},{"id":"https://openalex.org/keywords/indian-patients","display_name":"Indian patients","score":0.6039999723434448},{"id":"https://openalex.org/keywords/dietary-factors","display_name":"dietary factors","score":0.4050000011920929}],"concepts":[{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.9007804989814758},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.805428147315979},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6901350021362305},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.6745455861091614},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4713565707206726},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44972044229507446},{"id":"https://openalex.org/C2994119904","wikidata":"https://www.wikidata.org/wiki/Q1251001","display_name":"Drug response","level":3,"score":0.42125001549720764},{"id":"https://openalex.org/C2780194963","wikidata":"https://www.wikidata.org/wiki/Q903441","display_name":"Mesylate","level":2,"score":0.4179239571094513},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3729667663574219},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3700268864631653},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3699434995651245},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33252012729644775},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.08800598978996277},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:110348379","doi":"https://doi.org/10.15272/ajbps.v2i11.55","is_oa":false,"landing_page_url":"https://www.abacademies.org/articles/study-of-imatinib-mesylate-treated-patients-sufferening-from-chronic-myeloid-leukemia.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764445909","display_name":"Asian journal of biomedical and pharmaceutical sciences","issn_l":"2249-622X","issn":["2249-622X","6299-722X"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Asian journal of biomedical and pharmaceutical sciences","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1510546584","https://openalex.org/W1587979812","https://openalex.org/W1998593414","https://openalex.org/W2028959752","https://openalex.org/W2033629987","https://openalex.org/W2089483984","https://openalex.org/W2142969636","https://openalex.org/W2204543574","https://openalex.org/W2275311108","https://openalex.org/W2312804644","https://openalex.org/W2329648702","https://openalex.org/W2413775972"],"related_works":["https://openalex.org/W2088646795","https://openalex.org/W2329112167","https://openalex.org/W1986534053","https://openalex.org/W1984617193","https://openalex.org/W2045023664","https://openalex.org/W1522681695","https://openalex.org/W2981767993","https://openalex.org/W2012901486","https://openalex.org/W3048710221","https://openalex.org/W2568890057"],"abstract_inverted_index":{"Chronic":[0],"Myeloid":[1],"Leukemia":[2],"(CML)":[3],"is":[4],"also":[5],"an":[6],"attractive":[7],"target":[8],"for":[9,137],"a":[10,29],"rationally":[11],"designed":[12],"drug":[13,113,202],"development":[14],"programme":[15],"and":[16,68,99,130,165,195],"it":[17,193,196],"was":[18,55,91,97,159],"probably":[19],"the":[20,141,162,167,178,182,201],"first":[21,204],"form":[22],"of":[23,53,140,161,203],"leukemia":[24],"to":[25,111,124,149],"be":[26,122,147,150,188,198],"recognized":[27],"as":[28,200],"distinct":[30],"entity.":[31],"In":[32],"our":[33],"present":[34],"follow":[35,174],"up":[36,175],"study,":[37],"taken":[38],"normal":[39],"healthy":[40],"individuals,":[41],"Interferon":[42],"alpha,":[43],"Hydroxyurea,":[44],"Imatinib":[45,80,185],"mesylate":[46,81,186],"treated":[47,78],"patient.":[48],"The":[49,73,85,155],"percentage":[50],"response":[51,67,74,89,95],"rate":[52],"interferon":[54],"90%":[56],"in":[57,76,101,170,206],"which":[58],"10%":[59],"have":[60,82],"shown":[61,83],"complete":[62],"response,":[63],"30%":[64],"with":[65,70,79,184],"partial":[66],"50%":[69],"stable":[71,102],"condition.":[72,103],"rates":[75],"patients":[77,109],"87.5%.":[84],"overall":[86],"major":[87],"cytogenetic":[88,94],"(MCR)":[90],"2.5%,":[92],"Complete":[93],"(CCR)":[96],"77.5%":[98],"7.5%":[100],"This":[104,120,173],"clearly":[105],"demonstrates":[106],"that":[107,181],"Indian":[108,133],"respond":[110],"this":[112],"better":[114,152],"than":[115],"their":[116],"foreign":[117],"counter":[118],"parts.":[119],"may":[121,146,187],"due":[123],"multiple":[125],"reasons":[126],"including":[127],"food,":[128],"cultural":[129],"geographical":[131],"conditions.":[132],"people":[134],"are":[135],"known":[136],"more":[138],"consumption":[139],"species.":[142],"Their":[143],"food":[144],"ingredients":[145],"expected":[148],"viding":[151],"health":[153],"surveillance.":[154],"most":[156],"notable":[157],"finding":[158],"transformation":[160],"accelerated":[163],"phase":[164,169],"into":[166],"chronic":[168],"some":[171],"patients.":[172],"study":[176],"supports":[177],"global":[179],"view":[180],"therapy":[183],"continued":[189],"unless":[190],"resistance":[191],"against":[192],"develops":[194],"should":[197],"considered":[199],"choice":[205],"CML.":[207]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W110348379","counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
